Product Images Plavix

This is a graph displaying the cumulative event rate in percentage for either faial or non-faial vascular events over a period of 36 months of follow-up. The graph compares the use of aspirin versus Plavix. The data points for each medication are given at the 12, 18, 24, 30, and 36-month follow-up intervals.*

This is a graphical representation of the cumulative event rate (%) of Cardiovascular Death, Myocardial Infarction, and Stroke in patients who were given Placebo (+ aspirin) and Plavix (+ aspirin) over a follow-up period of up to 12 months. The graph shows that the Plavix treatment is more effective than placebo in reducing the incidence of these events. Other standard therapies as appropriate were also used.*

This appears to be a report on the results of a study comparing a placebo to clopidogrel (a medication used to reduce the risk of heart attack and stroke) in terms of reducing the risk of death. There were 1845 deaths (8.1%) in the placebo group and 1726 deaths (75%) in the clopidogrel group. The study found a 7% proportional risk reduction (p = 0.03) associated with clopidogrel. The number of days since randomization was also recorded.*

This is a medication description. The tablets contain 97.875mg of Clopidogrel bisulfate equivalent to 75mg Clopidogrel base. The manufacturer is Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. The tablets have an NDC code of 63653-11715 and a lot number of 9651527. They should be discarded after 05/12/2020. The remaining text is not legible. Possible side effects include diarrhea and stomach pains.*